Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
However, they also pose risks, such as pancreatitis and kidney issues, highlighting the need for careful monitoring by healthcare providers
Clinical trial data from the SURMOUNT-1 study showed that gastrointestinal adverse events were significantly more common during dose escalation periods (Jastreboff et al., 2022, NEJM)
Cardiovascular risk factors may return to pre-treatment levels, including increased blood pressure, cholesterol levels, and inflammatory markers
Long-term cardiovascular outcomes data are not yet available, as dedicated trials have not been completed
PMID: 2 SanzABSanchez-NioMDRamosAMOrtizA
Laboratory Study Number: 39241 RSR
